Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers
New Product for the Simple, Rapid, and Effective Debridement of Skin Ulcers
This study is testing a new liquid treatment for people with long-lasting (chronic) wounds, such as venous leg ulcers or diabetic foot ulcers. These wounds can be difficult to heal because they often contain dead tissue and bacteria. The new product is designed to help clean the wound and remove dead tissue, which may help the wound heal better. It will be compared to a commonly used treatment called Polyhexanide gel.
About 80 people aged 60 years or older will take part in this study. Each participant will be randomly assigned (like flipping a coin) to receive either the new treatment or the standard treatment. Neither the participant nor most of the study team will know which treatment is being used during the study to ensure fair results.
The study will last 4 weeks. Participants will attend eleven visits at the wound care center. During these visits, trained nurses will clean and treat the wound. The study team will:
- Measure the size of the wound
- Take small samples from the wound to check for bacteria
- Ask questions about pain and general health
- Check blood flow in the legs
- Perform blood tests at the beginning A specialist doctor will examine the wound at the start and at the end of the study to see how it has improved.
Overall, this study aims to find out if the new treatment can help wounds heal better and more quickly than current standard care.
Taking part in the study is completely voluntary. Participants can leave the study at any time without affecting their usual medical care. All personal and medical information will be kept confidential.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: María B Olivares, PhD
- Número de teléfono: 3634 562223279634
- Correo electrónico: molivares@udd.cl
Ubicaciones de estudio
-
-
Metropolitana de Santiago
-
Santiago, Metropolitana de Santiago, Chile
- Reclutamiento
- Universidad del Desarrollo
-
Contacto:
- María B Olivares, PhD
- Número de teléfono: 3634 562223279634
- Correo electrónico: molivares@udd.cl
-
Investigador principal:
- Daniela Constanza Espinoza, Nurse
-
Sub-Investigador:
- Isabel Aburto, Nurse
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria
A pure or mixed venous ulcer, or a diabetic, neuropathic, or neuroischemic foot ulcer, greater than or equal to 4 cm² and less than or equal to 30 cm² with critical colonization.
A duration of the ulcer greater than or equal to 2 months and less than or equal to 2 years.
Age over 60 years: due to the higher prevalence of ulcers in adults over 60 years of age.
An ankle-brachial index between 0.6 and 1.3.
Exclusion criteria
Morbid obesity (BMI > 35)
History of cancer treatment in the last year
Uncontrolled diabetes (Glycated Hemoglobin above 10 mg/dL)
Uncontrolled hypertension (blood pressure readings greater than 140/90 mmHg)
Patients with a known allergy to the components of the products under study.
Patients with signs of infection or undergoing antibiotic therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: BU002
Participants will received BU002 as debridement treatment.
|
BU002 is a composition intended for debridement and antibiofilm in wounds.
Otros nombres:
|
|
Comparador activo: Polihexanide Gel
Participants will received Polihexanide gel as debridement treatment.
|
Polihexanide combined with betaine is a debridement and antibiofilm comercial product.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in wound area
Periodo de tiempo: Baseline, 4 weeks
|
The total wound area it will be measure by an image software (Ekare Insight)
|
Baseline, 4 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in wound area covered by slough and necrotic tissue
Periodo de tiempo: Baseline, 4 weeks
|
The area will be measured by an image software (Ekare Insight)
|
Baseline, 4 weeks
|
|
Change in wound bacterial load
Periodo de tiempo: Baseline, 4 weeks
|
The bacterial burden will be measure by swab sampling, then culturing to determine colony forming units.
|
Baseline, 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2024-77
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .